New Jersey Division of Mental Health and Addiction Services

Evaluation Research Report of Findings:Medication-Assisted Treatment Initiative

Suzanne Borys, Ed.D. Robert P. Culleton, Ph.D.

Thursday, June 12, 2014

History and Legislation

- Bloodborne Disease Harm Reduction Act, BDHRA (P.L. 2006 C.99)
- \$10M for substance abuse Treatment and Evaluation Research
- Six Evaluation Cities: Camden, Atlantic, Trenton,
 Newark, Paterson, and Plainfield
- 3 Components of Medication-assisted Treatment Initiative (MATI):
 - Mobile Vans
 - Supportive Housing
 - Enhanced Subacute Detoxification

Mobile Van

- MATI offered free medication assisted treatment "on demand" to Syringe Access Program (SAP) participants and other opioid dependent individuals via
- 1) mobile medication units (MMU): motor coaches with safes for storage of medication, doctor's offices, lab station, computers, confidential counseling office, lavatory, and waiting area.
- 2) linked to fixed-site offices that provided counseling services based on client need.

Supportive Housing

- Eligibility criteria: homelessness or risk thereof
- Priority was given to current IDUs who were:
 - pregnant,
 - had children under 18, or
 - seeking reunification with removed children.
- Sobriety and abstinence not required.
- The Intensive Supportive Housing Team works with the consumer to motivate and support recovery.

Enhanced Detoxification

- Sub-acute 24-hour medically-monitored inpatient withdrawal management with 2 hours per week of individual counseling plus case management, and capable of treating:
 - pregnant women
 - poly-addicted persons (benzodiazepines)
 - MAT clients (traditional methadone)
 - medical condition not requiring acute care hospital services.

Evaluation Component

- Competitive bid selection process
- 9/2008: Award: Center For Alcoholism and Substance Abuse (CASA) Columbia University, NY
- 1/2008: Three components operational
- 10/01/08: Evaluation Research Began
- 1/30/14: Final Report Delivered

Purpose of the Evaluation

To determine if MATI increased treatment access, improved the continuum of care, and addressed barriers to recovery for disenfranchised, substance abusing, high HIV risk populations.

Evaluation Research Design: Mobile Van Component

Case-control study comparing cases enrolled in the MATI with matched controls enrolled in:

- 1) traditional methadone
- 2) drug-free outpatient

Evaluation Research Design: Enhanced Detoxification

- 1. NJSAMS data for all MATI patients
- Compare participants with nonparticipants
- 3. Two outcomes:
 - a) Length of stay
 - b) Treatment completion

Evaluation Research Design: Supportive Housing

- NJSAMS data for all supportive housing clients (SHC)
- Self-reported interview data collected from all SHCs upon "move-in" (baseline)
- Comparison of baseline data with data collected at 6, 12, and 18 months
- Pre- and Post- housing drug and treatment utilization, outcomes, and satisfaction

MATI & Housing Client Flow

Needle **Exchange Services**

Walk-in

<u>Treatment Eligibility &</u> Intake at one of six mobile or fixed sites.

- Income below poverty Level
- Uninsured
- Low Income
- History of IV drug Use
- Not currently in Treatment

Streamlined Intake Procedures at Admission

Housing

- Scattered Site
- Priority given to homeless individuals with families and pregnant women
- **Housing First Model**

Housing Admission B No treatment

Housing Admission A With treatment, 77%

Mobile Medication Services

Methadone/Suboxone

Office-Based Fixed Site Services

- 12 week Cognitive Behavioral Therapy group
- Counseling
- Outreach coordination
- Case Management
- Recovery Mentor Services

Possible referral to higher level of care or other services

Program Characteristics

	Atlantic City	Camden	Newark	Paterson	Plainfield	Trenton
SAP facility in city	never & share	never⊗share	never & share	never & share		
Mobile Unit						
Supportive Housing	CODI					
Patients served*	576	310	456	414	332	125
Patients interviewed	83	84	94	105	101	75
Referred from SAP**	23%	31%	40%	44%	19%	4%
Prescribed suboxone	28%	35%	26%	17%	28%	16%

Evaluation Aims

- 1. Describe MATI clients and experience
- 2. Compare outcomes with MAT, non-MAT:
 - A. heroin, other drug use
 - **B.** criminal justice involvement
 - C. injection drug use
 - D. HIV risk
 - **E.** Treatment LOS
 - F. Medical utilization and costs:
 - **1) MMU**
 - 2) Supportive Housing

Research Procedures

Participants

All Clients

2,259 MATI Participants

- 6 sites -

NCADD interviewed 542 of these participants – 6 sites –

71 clients in supportive housing – 2 sites – NCADD interviewed all

Study Procedures

Baseline

- consent
- demographics
- ASI/drug use history
- clinical characteristics
- use of services



Follow-up interviews


- 6, 12, 18 months
- drug use
- clinical symptoms
- use of services
- experience with services
- urine drug screen



Sources of information

- NCADD interview
- NJSAMS
- Case manager logs

Selection of Administrative Sample



- 1. Propensity score balanced on
- race/ethnicity
- housing stability
- substance use severity
- criminal justice events
- treatment history
- mental illness
- 2. Propensity score weights were applied to regression models of retention in treatment, treatment completion, and medical service

Patient Characteristics

 Both MATI and non-MAT groups had a large proportion of African-Americans, Latinos, uninsured, and homeless.

 MATI patients had greater substance use severity than traditional methadone and non-MAT patients

Treatment Retention

- LOS for MATI patients was longer than it was for non-MAT patients.
- LOS for MATI patients prescribed methadone
 - no different from traditional methadone patients
 - longer than for those choosing suboxone*
- *Suboxone dosage correlated with LOS. Failure to prescribe at clinically significant doses may have undermined client LOS and may explain the lower-than-methadone LOS.

Hospital Utilization and Costs

- MATI and non-MAT patients showed no difference in hospital and emergency department (ED) utilization or costs.
- Compared to traditional methadone patients, MATI patients
 - had lower ED costs
 - were less likely to initiate inpatient hospitalizations

Treatment Access

- O Low wait times to access treatment.
- In most cases, once intake was done, treatment started same day.
- People reported MATI was significantly easier to access compared to past experiences.
- Clients preferred the mobile van.

MATI Interviews: Key Findings

- There were significant decreases in:
 - OIDU
 - Use of unclean needles
 - Use of substances (heroin, cocaine, alcohol to intoxication)
 - Detention or incarceration
 - Engagement in illegal activity for profit
- Positive outcomes are associated with cost savings for the patient and the state.

Enhanced Detoxification

MATI patients participating in enhanced detox were:

- omore likely to be African-American and age 36-45.
- oless likely to be IDUs.
- demonstrate a longer LOS than MATI patients that did not participate.

Supportive Housing Outcomes

- Given the option, 77% of supportive housing clients entered treatment.
- Supportive Housing clients demonstrated:
 - o reduction in IDU heroin use.
 - lower average ED and inpatient hospital costs but small sample size prevented seeing a statistical difference.
 - Successful parent-child reunifications (20%)

Summary

- MATI reached African American, Latino, homeless, uninsured persons who are:
 - often found in non-MAT programs
 - onot well represented in MAT programs
- O MATI patients showed:
 - o LOS (1.3 yr) comparable to MAT patients
 - LOS significantly longer than non-MAT patients.

Conclusion

The Medication-Assisted Treatment Initiative (MATI) proved an effective public health response to heroin use by:

- improving treatment access for homeless, medically-indigent heroininjecting persons.
- reducing IVDU, HIV risk, social and economic costs of the chronic disease of addiction.